L-Citrulline
L-citrulline can increase nitric oxide-mediated vasodilation and may add to VIP-related flushing or low blood pressure.
Recommendation: Avoid combining if prone to hypotension, syncope, or using antihypertensive drugs.
Peptide ·Insufficient evidence ·Reviewed May 2026
VIP is an endogenous 28-amino-acid neuropeptide with vasodilatory, bronchodilatory, secretory, and immunomodulatory effects through VPAC receptors. Intranasal, inhaled, or injectable wellness use is not FDA-approved, although related aviptadil formulations have been studied for pulmonary and inflammatory disorders. Evidence for CIRS or general immune-repair protocols is limited and off-label.
The bottom line
Evidence rating insufficient. Most-documented uses: studied for pulmonary immune modulation, potent vasodilatory signaling, mucosal and neuroimmune research interest. 3 sources indexed (1991–2010), with 3 interaction records on file.
Core mechanism
VIP activates VPAC1 and VPAC2 G-protein-coupled receptors, increasing cAMP signaling in immune, epithelial, smooth-muscle, and nervous-system tissues. This can relax vascular and airway smooth muscle, influence mucosal secretion, and shift inflammatory cytokine patterns. These effects also explain risks such as flushing, hypotension, tachycardia, headache, and diarrhea.
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Investigational Inhaled VIP.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Dose: Protocol-specific inhaled dosing1,2
Timing: Study protocol only
Small human studies do not establish routine use.
Dose: No FDA-approved dose
Timing: Per clinician if used
Evidence is limited and diagnosis should be rigorous.
Dose: No approved dose
Timing: Not applicable
Vasodilatory adverse effects can be clinically important.
Where this appears in the symptom-to-supplement map, ranked by relevance.
VIP has immunoregulatory biology but limited clinical evidence.1,3
Do not replace diagnosed disease care.
CIRS-related claims are off-label and weakly evidenced.
Rule out common causes.
Pulmonary studies exist, but dyspnea can be urgent and VIP is not standard treatment.2
Seek care for respiratory symptoms.
L-citrulline can increase nitric oxide-mediated vasodilation and may add to VIP-related flushing or low blood pressure.
Recommendation: Avoid combining if prone to hypotension, syncope, or using antihypertensive drugs.
Magnesium can lower blood pressure in some users and may add to VIP-related dizziness.
Recommendation: Monitor blood pressure in any supervised context; avoid self-use.
Melatonin-related sleepiness may worsen dizziness from VIP-related hypotension.
Recommendation: Avoid driving or hazardous activity if dizziness occurs.
Search all 3 interaction records for VIP (Vasoactive Intestinal Peptide) →
Numbered references. Citations throughout the page link here.
Inhaled VIP altered immune readouts
Pulmonary hemodynamic effects were observed
VIP is active in lung tissues
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.